[A18-86] Damoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2019
Commission awarded on 19.12.2018 by the Federal Joint Committee (G-BA).
Treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia A (congenital factor VIII deficiency)
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.